Nyrada Inc Market Cap ($77.13 Million)
Market Cap & Net Worth: Nyrada Inc (NYR)
Nyrada Inc market cap. Nyrada Inc (AU:NYR) has a market capitalization of $77.13 Million (AU$109.00 Million) as of November 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #20009 globally and #659 in its home market, demonstrating a -10.10% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nyrada Inc's stock price AU$0.45 by its total outstanding shares 244949705 (244.95 Million). Also see Nyrada Inc (NYR) cash conversion ratio for how efficiently the company converts equity into cash flow.
Nyrada Inc Market Cap History (2020–2026)
Nyrada Inc market cap history from 2020 to 2026. Data shows growth from $41.60 Million to $77.13 Million (9.83% CAGR). Check Nyrada Inc share price for real-time trading data and today's change.
Nyrada Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nyrada Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Nyrada Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
80.99x
Nyrada Inc's market cap is 80.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $41.60 Million | $1.13 Million | -$5.77 Million | 36.96x | N/A |
| 2021 | $41.60 Million | $2.34 Million | -$3.53 Million | 17.81x | N/A |
| 2022 | $25.13 Million | $1.09 Million | -$3.97 Million | 22.98x | N/A |
| 2023 | $3.81 Million | $1.43 Million | -$7.82 Million | 2.67x | N/A |
| 2024 | $16.29 Million | $3.24 Million | -$1.39 Million | 5.03x | N/A |
| 2025 | $194.12 Million | $2.40 Million | -$4.85 Million | 80.99x | N/A |
Competitor Companies of NYR by Market Capitalization
Companies near Nyrada Inc in the global market cap rankings as of November 6, 2026. Also see total assets of Nyrada Inc for a full breakdown of the balance sheet.
Key companies related to Nyrada Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #176 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #405 globally with a market cap of $69.48 Billion USD ( AU$98.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #499 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #176 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $542.50 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $902.90 |
| #405 | CSL Ltd | AU:CSL | $69.48 Billion | AU$202.40 |
| #499 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $241.46 |
Market Capitalization of Nyrada Inc (2020–2026)
Market capitalization of Nyrada Inc from 2020 to today. Between 2020 and today, Nyrada Inc's market cap moved from $41.60 Million to $ 77.13 Million, with a yearly change of 9.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$77.13 Million | -60.27% |
| 2025 | AU$194.12 Million | +1091.49% |
| 2024 | AU$16.29 Million | +327.27% |
| 2023 | AU$3.81 Million | -84.83% |
| 2022 | AU$25.13 Million | -39.58% |
| 2021 | AU$41.60 Million | 0.00% |
| 2020 | AU$41.60 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Nyrada Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $77.13 Million USD |
| MoneyControl | $77.13 Million USD |
| MarketWatch | $77.13 Million USD |
| marketcap.company | $77.13 Million USD |
| Reuters | $77.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nyrada Inc
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporat… Read more